Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Access the best science of the year, wherever you are
The place to share your research, explore promising areas of development and engage with the international oncology community
Gain a deeper understanding of the current and future therapies for the treatment of this tumour type. Watch live and get 2 ESMO-MORA category 1 points
A valuable assessment tool for practicing medical oncologists and an excellent opportunity for medical oncologists in training to assess their knowledge.
Online application is now open until 9 May 2023
Online application is open until 4 April 2023
Online application is open until 10 April 2023
Online application is open until 3 April 2023
Discover how the ESMO Guidelines can assist in your decision making to optimise patient care. ESMO Member? Take the CME test and get 1 ESMO-MORA category 1 point
Access the resources for this striking presentation of practice-changing data in advanced endometrial cancer
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody
Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel
ESMO is contributing to making European Union legislation stricter on exposure limits for air pollution and asbestos to prevent new lung cancer cases
The key to overcoming barriers to effective prevention and treatment in resource-restricted settings involves cooperation between multiple organisations, including medical societies, patient groups, pharmaceutical companies and regulatory agencies
Recipient of the Heine H. Hansen Award 2023, Prof. Paul Baas charts the course of mesothelioma treatment over the last 30 years and warns that progress has been made only in some areas of the world
Findings from an analysis of two independent study cohorts
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases
Data from two studies improve knowledge of how to treat patients with a disease harbouring this molecular alteration and how to monitor response to treatment
Additional exploratory analyses of the phase III CheckMate 816 trial reveal that event-free survival at 3 years is not influenced by surgical parameters and suggest that tumour inflammation may be a useful predictive biomarker
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy
Findings from the NRG-GY018 study
Patients consider side-effects of the KRAS G12C inhibitor to be more tolerable and to have less interference on their lives than those due to docetaxel
Updated results from the CHRYSALIS trial also suggest a number of biomarkers predictive of sustained clinical benefit with the EGFR–MET bispecific antibody
In the European Parliament (EP) and Council of Ministers, discussions are currently progressing on the legislative proposal for establishing the European Health Data Space (EHDS).
Findings from an analysis of two independent study cohorts
Findings from the NRG-GY018 study
Findings from a post hoc exploratory analysis of the TITAN study
Evidence for efficacy is based on the results from the PODIUM-201 study
Droplet digital PCR detects BRAF allele fraction in ctDNA with high reproducibility and sensitivity, offering an alternative to NGS
Evidence for efficacy is based on the results from the Study CDRB436G2201
Findings from the NEOSTAR phase II platform study
Findings from a large comprehensive analysis do not support the evidence of a common genetic clonal alteration
Findings from the ProtecT study after 15 years of follow-up
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)
ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today
The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.
The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally but the molecular characteristics of the disease remain unexplored for the majority of patients around the world.
The ESMO Asia Congress 2022 will be held in person in Singapore and virtually between 2-4 December 2022.
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced today that the 2023 Heine H. Hansen Award is conferred on Paul Baas for his outstanding contribution to thoracic oncology research
ESMO has announced today that the 2023 ESMO TAT Honorary Award is presented to Susan Bates
ESMO is pleased to announce that the nomination process for the 2023 ESMO Society Awards is now open.
ESMO renews its support to World Cancer Day (WCD) joining the #CloseTheCareGap campaign led by the Union for International Cancer Control (UICC).
Andrés Cervantes started his two-year mandate as ESMO President on 1 January 2023.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
With more than 2.2 million new cases and nearly 1.8 million deaths in 2020, lung cancer represents 11.4% of the 19,292,789 new cases of cancer worldwide and 18% of its mortality.
The European Society for Medical Oncology (ESMO) has announced today that the winner of the ESMO Award for Immuno-Oncology 2022 is conferred on Nina Bhardwaj for her outstanding contribution to cancer immunology research.
From ELCC 2023:
Liposomal irinotecan does not offer significantly better overall survival than topotecan for patients with small-cell lung cancer that has progressed during or after first-line platinum-based chemotherapy
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Argentina
Germany
Spain
United Arab Emirates
Netherlands
Spain
Switzerland
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
